“crohns-disease” Archives

in
Entry Author Date Location
Finch Therapeutics Fetches $90M to Advance Microbiome Drug Pipeline 09/17/20 Boston
Roche Gut Disease Drug Produces Mixed Results in Late-Stage Trials 08/11/20 National
Applied Molecular Plots IPO to Back Transport of Biologic Drugs to Gut 05/20/20 San Francisco
From Overseas, Legend Biotech and Calliditas Therapeutics Eye the Nasdaq 05/15/20 New York
Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19) 04/22/20 National
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch 03/26/20 New York
PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome 06/26/19 Boulder/Denver
With Yale Tech and $12M, Artizan Aims for Root Cause of Gut Disease 06/10/19 Boston
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track 03/11/19 New York
Arena’s Comeback Continues with $800M Deal for Lung Disease Drug 11/15/18 San Diego
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs 11/14/18 San Diego
Sangamo Bags TxCell, and a Next-Gen Cell Therapy Tech, for $84M 07/23/18 San Francisco
The Revolution in Inflammation Drug Development 05/15/18 Boston
Arena Pharma’s Revamp Gains Traction With New Data For GI Drug 03/20/18 San Diego
FDA Refuses to Review Celgene’s MS Drug, Says File “Insufficient” 02/27/18 New York
Celularity Raises $250M to Make Stem Cell Treatments for Cancer & More 02/15/18 New York
Theravance Snares $100M From Janssen in Stomach Drug Deal 02/07/18 San Francisco
Landos Joins Garabedian’s Bio Startup Accelerator Xontogeny, Gets $10M 09/21/17 Boston
SetPoint Nabs $30M For More Tests of Bioelectric Device as RA Therapy 08/28/17 San Francisco
Protagonist, Janssen Ink Development Deal for Crohn’s Disease Drug 05/30/17 San Francisco
Early Data for Celgene’s Oral Crohn’s Drug Gets Mixed Reaction 10/17/16 New York
Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More 10/07/16 National
Biotech Roundup: CRISPR’s 3rd IPO, Gender Diversity, Buyouts & More 09/16/16 National
Sofinnova, Atlas Put $35M Into Delinia to Tackle Autoimmune Diseases 09/14/16 Boston
Celgene Touts Data From Early Study of Oral GI Drug 09/12/16 Boston
Second Genome Replaces DiLaura as CEO, Brings Series B to $51M 07/13/16 San Francisco
Probing Gut Microbiome, Second Genome Nabs $43M To Push Colitis Drug 04/20/16 San Francisco
New PureTech Startup Commense Aims to Protect Babies From Disease 03/31/16 Boston
Synlogic Nabs $40M, Prepares To Put Modified Microbes Into Patients 02/17/16 Boston
Seres Inks Nestlé As Potential $2B Partner; Key Microbiome Data Soon 01/11/16 Boston
Page 1 of 3 next page »